[Vasodilatation and positive inotropic effect of the phosphodiesterase inhibitor enoximone].
The comparison of two invasive studies using intravenous application of the phosphodiesterase enoximone demonstrated unchanged cardiac output in patients with dilated cardiomyopathy NYHA II-III, and increased cardiac output (from 3.22 +/- 1.15 to 5.04 +/- 2.05 l/min; p less than 0.01) in acute heart failure. This comparison of hemodynamic parameters in addition to studies on myocardial oxygen consumption support the use of intravenous enoximone in acute heart failure, whereas the long-term application of enoximone in chronic heart failure is judged to be critical.
Holubarsch
C
C
Medizinische Universitätsklinik Freiburg, Universität Freiburg.
Hasenfuss
G
G
Thierfelder
L
L
Heiss
H W
HW
Just
H
H
D002302:Cardiac Output / Q000187:drug effects*; D002303:Cardiac Output, Low / Q000188:drug therapy; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy; D002316:Cardiotonic Agents; D004305:Dose-Response Relationship, Drug; D017335:Enoximone; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D009200:Myocardial Contraction / Q000187:drug effects*; D010726:Phosphodiesterase Inhibitors
D002316:Cardiotonic Agents; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D017335:Enoximone
Vasodilatation und positive Inotropie des Phosphodiesterasehemmers Enoximon.